Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02283970
Other study ID # K11
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 2012
Est. completion date July 2017

Study information

Verified date August 2018
Source Gruppo di Ricerca GISSI
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Prospective longitudinal study on four small groups of surgical patients affected by: BAV with isolated regurgitation, BAV associated with aorta dilatation, or both and BAV with isolated stenosis in over 60 year-old patients.

The aim of the study is to select homogeneous small groups of surgical patients with the same subtype of BAV and same aortic behaviour and identify markers/predictors of favorable-unfavorable aortic wall evolution to evaluate if there is a BAV phenotype more likely to be considered at high risk for aortic degeneration.


Description:

The aim of the study is to select homogeneous small groups of surgical patients with the same subtype of BAV and same aortic behaviour and identify markers/predictors of favorable-unfavorable aortic wall evolution to evaluate if there is a BAV phenotype more likely to be considered at high risk for aortic degeneration. The study will focus on multiple aspects of BAV disease. What follows will be considered and combined:

Aortic valve, aorta root and ascending aorta morphology The use of two- (2DE) and three-dimensional (3DE) trans-thoracic (TTE) and/or transoesophageal (TOE) echocardiography can identify all kind of BAV morphology (leaflet position and coronary ostia displacement). It also gives quali- quantitative information about root and ascending aorta morphology and size.

BAV genetics Recently, missense mutations in the NOTCH1 gene have been shown to be associated with calcific aortic valve disease plus BAV. However mutations in the NOTCH1 gene only partially explain the presence of BAV in the absence of other syndromic diseases (i.e. Marfan Syndrome, Loeys Dietz Syndrome type I and II and Ehlers Danlos type IV Syndrome).

BAV Histology In all enrolled patients, during operation, tissue samples will be collected from valve cusps (in case of valve involvement), aortic wall (aortic root, concavity or convexity of ascending aorta) or from both of them. Samples will be analyzed in order to classify medial and intimal disruption and changes.

Study Design and Setting of the Study The first step will consist in enrolling patients with echocardiographic diagnosis of BAV and indication for surgery. From the echo data, aortic valve, as well as aortic root and ascending aorta morphology will be assessed in order to classify patients in each phenotypic pattern. The echo images from participating centres will be sent to an echo core lab for quali- quantitative analysis (see below) and all data will be recorded in a specific database.

The second step will consider first-degree relatives of each enrolled patient. The investigators will ask every first degree relative to perform a screening TTE in order to find out, according to familiar aetiology of BAV, the presence of BAV and/or associated disease (aortic root or ascending aorta enlargement or coronary ostia displacement).

The third step will consist in collecting blood samples from each patient and from any of first-degree relatives with BAV diagnosis. BAV-specific genetic tests will be performed and all data will be recorder in a specific database.

The fourth intraoperative step will consist in :

1. performing a 3D TOE in order to study the geometry and the dynamic behaviour of the aortic valve and root and

2. in collecting surgical tissue samples: during operation there will be described precisely the anatomy of the valve and the aorta in detail; then, from the usual site of surgery, there will be collected valve and aortic wall samples in order to perform histological, immunohistochemical and genetics tests.

Blood and surgical samples will be stored in a bio-bank for future analysis related to this protocol.


Recruitment information / eligibility

Status Completed
Enrollment 62
Est. completion date July 2017
Est. primary completion date July 2014
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Men and women over 18 years-old and under the age of 60 (age selection will prevent from enrolling patient with age-related valve and aortic wall degeneration). For the BAV stenosis group there will be considered patients over 60 years-old: including the most frequent form of BAV disease and the commonest age, this group could be used as a control group compared to the outlier ones.

- Echo diagnosis of BAV and indication to surgery:

BAV with isolated regurgitation, BAV with normal valvular function but associated aorta dilatation, BAV with both valve regurgitation and aortic dilatation BAV with isolated stenosis

- Signed informed consent

Exclusion Criteria:

- Patient with a previous cardiac or great vessels surgery

- coexistent coarctation of the aorta

- non-associated cardiac diseases: valve disease (other than aortic), ischemic disease, congenital heart disease.

- Marfan syndrome or other connective tissue disorders involving aortic valve and aortic wall disease (history of disease or clinical signs).

- Other conditions/circumstances likely to lead to poor study adherence (e.g. psychological or organizational reasons).

- Serious disease other than aortic, severely limiting life expectancy.

- Patients who refuse to give informed consent

Study Design


Locations

Country Name City State
Italy Casa Di Cura Villa Sant'Anna Catanzaro CZ
Italy Aou Careggi Firenze FI
Italy Ospedale Dell'Angelo Mestre VE
Italy Centro Cardiologico Monzino Milano MI
Italy Ospedale Niguarda Milano MI
Italy Ospedale San Raffaele Milano MI
Italy Ospedale San Camillo Roma
Italy Irccs Policlinico San Donato San Donato Milanese MI
Italy Azienda Osp. Univ. S. Giovanni Battista Torino
Italy Aou Santa Maria Della Misericordia Udine UD

Sponsors (1)

Lead Sponsor Collaborator
Gruppo di Ricerca GISSI

Country where clinical trial is conducted

Italy, 

References & Publications (1)

Merlanti B, De Chiara B, Maggioni AP, Moreo A, Pileggi S, Romeo G, Russo CF, Rizzo S, Martinelli L, Maseri A; VAR Study Group. Rationale and design of GISSI OUTLIERS VAR Study in bicuspid aortic valve patients: prospective longitudinal, multicenter study to investigate correlation between surgical, echo distinctive features, histologic and genetic findings in phenotypically homogeneous outlier cases. Int J Cardiol. 2015 Nov 15;199:180-5. doi: 10.1016/j.ijcard.2015.06.182. Epub 2015 Jul 6. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Mutation in NOTCH1 gene The strongest causative gene associated with BAV is NOTCH1. Its 34 coding exons will be sequenced to search for variants likely to be causative.
The presence of sequence variation will be confirmed using a different method, starting from a new amplification (RFLP or High Resolution Melting-HRM). The pathogeneticity of the mutation will be evaluated screening 500 DNA controls (1000 chromosomes) to estimate the alleles' frequencies (HRM; ABI Prism 7900HT). Finally a familial segregation analysis will be performed to verify the association with the disease.
Enrollment
See also
  Status Clinical Trial Phase
Completed NCT03314857 - China XT: Safety and Effectiveness of Edwards Lifesciences SAPIEN XT THV in the Chinese Population N/A
Completed NCT03666351 - Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease Phase 4
Recruiting NCT06034028 - J-Valve TF Early Feasibility Study N/A
Completed NCT05515848 - Aortic Valve-sparing Root Replacement, According to the Inclusion Technique Described by Tirone David
Active, not recruiting NCT03549091 - Accuracy of Left Subclavian Regurgitation Evaluated by Ultrasound Doppler and 4D Flow MRI N/A
Completed NCT01598844 - JUPITER Study: Transapical Aortic Valve Implantation for Aortic Regurgitation
Active, not recruiting NCT03466918 - China S3: Safety and Effectiveness of Edwards Lifesciences SAPIEN 3 THV in the Chinese Population N/A
Active, not recruiting NCT04415047 - The JenaValve ALIGN-AR Pivotal Trial N/A
Not yet recruiting NCT05319171 - Performance of Currently Available traNscaTHEter Aortic Valve Platforms in Inoperable Patients With Pure Aortic regurgitatiON of a Native Valve. The PANTHEON International Project.
Completed NCT05774795 - LOng-Term Fate of Moderate Aortic Regurgitation Left Untreated at the Time of Mitral Valve Surgery
Terminated NCT02351726 - Mitroflow DL Post Approval Study- North America N/A
Completed NCT00624884 - Velocity Vector Imaging in Patients With Moderate-to-Severe Aortic Regurgitation N/A
Withdrawn NCT05409378 - HLT® Meridian® TAVR Valve System Early Feasibility Study for Aortic Regurgitation N/A
Recruiting NCT04038879 - Comparison Study of Echocardiography and Cardiovascular Magnetic Resonance Imaging in the Assessment of Mitral and Aortic Regurgitation
Completed NCT05332184 - Cardiac T1 Mapping Enables Risk Prediction of LV Dysfunction After Surgery for Aortic Regurgitation
Completed NCT01400841 - HAART Model 300 Annuloplasty Ring N/A
Not yet recruiting NCT02633423 - Expiratory Flow Limitation and Mechanical Ventilation During Cardiopulmonary Bypass in Cardiac Surgery N/A
Completed NCT00976625 - Diastolic Dysfunction in Aortic Regurgitation N/A
Enrolling by invitation NCT05714293 - CT-evaluation of Coronary Ostia Height After Surgical Aortic Valve Replacement. N/A
Recruiting NCT02974920 - Rivaroxaban or Aspirin for Biological Aortic Prosthesis Phase 4